TLR2 and exocrine pancreatic carcinoma: Consistently, preclinical studies using genetic or antibody-mediated TLR2 blockade (e.g., OPN-301) inhibited tumorigenesis in gastric and pancreatic carcinomas, and head and neck cancers [201].